v3.25.2
Statements of Cash Flows (Unaudited) - USD ($)
$ in Thousands
 6 Months Ended
Jun. 30, 2025
Jun. 30, 2024
Cash Flows from Operating Activities:    
Net loss $ (915) $ (13,390)
Adjustments to reconcile net loss to net cash used in operating activities:    
Issuance of common shares - equity fee on equity offerings to Fortress Biotech 216 163
Stock-based compensation expenses 83 (542)
Depreciation expense 34 569
Amortization of operating lease right-of-use assets 7 128
Settlement of payables (796) (709)
Loss on disposal of property and equipment 0 29
Asset impairment 0 2,649
Gain on lease termination (394) (314)
Changes in operating assets and liabilities:    
Prepaid expenses and other assets 28 672
Other receivables 435 167
Accounts payable and accrued expenses (1,190) 1,690
Payable and accrued expenses - related party (163) 1,470
Lease liabilities (73) (238)
Net cash used in operating activities (2,728) (7,656)
Cash Flows from Investing Activities:    
Proceeds from the sale of property and equipment 1,165 0
Net cash from investing activities 1,165 0
Cash Flows from Financing Activities:    
Proceeds from issuance of common shares, net of offering costs - equity offering 6,782 5,264
Proceeds from issuance of common shares, net of offering costs - At-the-Market offering 599 0
Proceeds from warrant exercises 0 3
Proceeds from issuance of common shares under ESPP 0 48
Net cash provided by financing activities 7,381 5,315
Net change in cash, cash equivalents and restricted cash 5,818 (2,341)
Cash, cash equivalents and restricted cash, beginning of the period 6,839 6,984
Cash, cash equivalents and restricted cash, end of the period 12,657 4,643
Supplemental disclosure of noncash activities:    
Issuance of common shares - Founders Agreement and equity fee to Fortress $ 611 $ 591

Source

PDF HTML 10-Q Filing
ZIP XLS HTML XBRL